Concepedia

Rachel Courtney

RC

16

Publications

2.4K

Citations

15

H-Index

2003

Active since

Affiliations

Pfizer (United States)(Current)

University of Bologna

Dana-Farber Cancer Institute

University of Birmingham

Memorial Sloan Kettering Cancer Center

Rachel Courtney is an author at Pfizer (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top concepts

Publications per year

2003–2015

16

Publications

16

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

Keith T. Flaherty, Patricia LoRusso, Angela DeMichele et al. · Clinical Cancer Research · 2011 · 359 citations

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

Rachel Courtney, David Wexler, Elaine Radwanski et al. · British Journal of Clinical Pharmacology · 2003 · 324 citations · Full text

Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy Adults

Rachel Courtney, Sudhakar M. Pai, Mark Laughlin et al. · Antimicrobial Agents and Chemotherapy · 2003 · 299 citations · Full text

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

John P. Leonard, Ann S. LaCasce, Mitchell R. Smith et al. · Blood · 2012 · 291 citations · Full text

Disposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects

Philip A. Krieter, Brian Flannery, Timothy J Musick et al. · Antimicrobial Agents and Chemotherapy · 2004 · 211 citations · Full text

, , +13

Rows per page

1–5 of 16